FILING ANALYSIS · THURSDAY, NOVEMBER 5
Climb Bio, Inc. CLYM — 8-K: Results of Operations and Financial Condition
neutral
Climb Bio reported promising Phase 1 data for CLYM116 and initial Phase 2 data for budoprutug, with a cash runway into the second half of 2028, but no quantified surprises or significant updates that would move the stock beyond 1.5% in a week
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →